ViiV Healthcare’s Tivicay Approved for Children with HIV

The FDA has approved ViiV Healthcare’s Tivicay and Tivicay PD (dolutegravir) tablets with other antiretroviral treatments to treat human immunodeficiency virus (HIV) infections in pediatric patients at least four weeks old who weigh at least 6.61 pounds.

The approval was based on the results of a clinical trial in which 62 percent of patients given the treatments had an undetectable viral load by 24 weeks, increasing to 69 percent of patients at 48 weeks.

Tivicay was previously approved for children ages six years and older who weigh more than 66 pounds.